Liquid biopsy, multi-cancer early detection, and artificial intelligence: new frontiers in cancer screening from a technological and immunological perspective.
Combining blood tests, immune signals, and artificial intelligence improves multi-cancer early detection screening strategies.
This Front Immunol review synthesizes the landscape of liquid biopsy technologies, AI-based interpretation, and multi-cancer early detection platforms, with emphasis on immunological signals that complement DNA-based cfDNA approaches. The review provides a framework for next-generation MCED screening strategies and their clinical implementation challenges.
What the study was
- Study design
- Comprehensive narrative review
- Population
- General cancer screening population (MCED applications)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Frontiers in immunology
Why it surfaced
Front Immunol; comprehensive MCED + AI + liquid biopsy review; PMC open access; useful pipeline intelligence context.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.